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Abstract
Loss of function mutations in SETD1A are the first experi-
ment-wide significant findings to emerge from exome se-
quencing studies of schizophrenia. Although SETD1A is 
known to encode a histone methyltransferase, the conse-
quences of reduced SETD1A activity on gene expression in 
neural cells have, to date, been unknown. To explore tran-
scriptional changes through which genetic perturbation of 
SETD1A could confer risk for schizophrenia, we have per-
formed genome-wide gene expression profiling of a com-
monly used human neuroblastoma cell line in which SETD1A 
expression has been experimentally reduced using RNA in-
terference (RNAi). We identified 1,031 gene expression 
changes that were significant in two separate RNAi condi-
tions compared with control, including effects on genes of 
known neurodevelopmental importance such as DCX and 
DLX5. Genes that were differentially expressed following 
SETD1A knockdown were enriched for annotation to meta-
bolic pathways, peptidase regulator activity and integrin-
mediated regulation of cell adhesion. Moreover, differential-
ly expressed genes were enriched for common variant asso-
ciation with schizophrenia, suggesting a degree of molecular 
convergence between this rare schizophrenia risk factor and 
susceptibility variants for the disorder operating more gen-
erally. © 2019 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Large-scale genomic studies have successfully identi-
fied many risk loci for schizophrenia [1]. These include 
common genetic variants with individually weak effects 
on susceptibility, as well as rare variants of stronger effect. 
Building on earlier observations [2], a recent large-scale 
exome sequencing study identified loss of function (LoF) 
variants in the SETD1A gene (encoding SET Domain 
Containing 1A) as the first exome-wide significant ge-
netic risk factor for schizophrenia [3]. Although rare in 
the disorder, LoF mutations in SETD1A are substantially 
depleted in people without a neuropsychiatric diagnosis, 
identified in only 2 of 45,376 such individuals (compared 
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to a frequency of 0.13% in schizophrenia cases) in the 
study of Singh et al. [3]. Furthermore, rare, heterozygous 
LoF mutations in SETD1A have been found in individu-
als diagnosed as having developmental disorders and 
childhood apraxia of speech [3, 4].
These mutations (nonsense, frameshifting and splice 
site mutations) are broadly distributed throughout 
SETD1A and are predicted to lead to premature transla-
tional termination before the conserved SET domain en-
coded by exons 16–19. Although the mutant allele may be 
transcribed, it is likely to be degraded by nonsense medi-
ated decay effectively resulting in SETD1A haplo-insuffi-
ciency. It is therefore unlikely that the protein produced 
from the mutant allele may behave in a dominant nega-
tive manner. These heterozygous mutations are therefore 
predicted to result in only 1 functional copy of SETD1A.
In contrast to the majority of loci identified by ge-
nome-wide association studies (GWAS) where the target 
gene(s) and pathogenic mechanism are often unclear [5], 
this finding establishes haplo-insufficiency of SETD1A as 
a defined genetic risk factor for schizophrenia.
Functional investigation of genes at schizophrenia risk 
loci (e.g. [6–9]) can serve as a starting point for uncover-
ing the biological basis of the disorder. SETD1A is known 
to encode a broadly expressed protein that regulates chro-
matin structure by catalyzing the methylation of histone 
H3 at lysine residue 4 (H3K4me). Methylation of H3K4 
is indicative of positive gene regulation, with mono-
methylation (H3K4me1) enriched at active and primed 
enhancers, while trimethylation (H3K4me3) is usual- 
ly found at the promoters of actively transcribed genes 
[10]. Reduced SETD1A activity through pathogenic LoF 
mutations is therefore likely to have a major impact on 
gene expression via alterations to the histone code. While 
gene expression changes have been described following 
SETD1A knockdown in non-neural cells [11–13], to date, 
no such investigations have been reported in cells of neu-
ral origin. Therefore, in order to explore transcriptional 
changes through which genetic perturbation of SETD1A 
could confer risk for schizophrenia, we have performed 
genome-wide gene expression profiling of a human neu-
ral cell line in which SETD1A expression has been exper-
imentally reduced.
Materials and Methods
Cell Culture and siRNA Transfection
SH-SY5Y cells (ATCC) were maintained in DMEM/F12 con-
taining glutamine and 10% fetal bovine serum. Knockdown of en-
dogenous SETD1A expression was achieved by RNA interference 
(RNAi), using two non-overlapping siRNA targeting full-length 
SETD1A mRNA (Ensembl ENSG00000099381) in two sepa- 
rate RNAi conditions (ThermoFisher Scientific). Silencer select 
SETD1A siRNA #1 (s18789) targets exons 2/3 of SETD1A, and si-
lencer select SETD1A siRNA #2 (s18790) targets exon 14. A nega-
tive control siRNA (ThermoFisher Scientific), with no sequence 
similarity with any human transcript, was used for the control 
comparison condition. Twenty-four hours before transfection, 
cells were seeded into T25 flasks at a density of 300,000 cells/flask. 
10 nM control siRNA, SETD1A siRNA #1 or SETD1A siRNA #2 
were transfected into individual flasks using Lipofectamine 
RNAiMAX (ThermoFisher Scientific), with 4 biological replicates 
per condition. In order to estimate transfection efficiency, an ad-
ditional T25 flask of seeded cells was transfected with 10 nM 
BLOCK-iTTM Alexa Fluor® Red Fluorescent Control oligonucle-
otide (ThermoFisher Scientific), using the same reagent, and visu-
alized after 24 h by fluorescence microscopy. Cells were harvested 
for RNA extraction 96 h after transfection.
RNA Extraction and cDNA Synthesis
Total RNA was extracted from control and SETD1A RNAi con-
ditions using Trizol (ThermoFisher Scientific), following the man-
ufacturer’s instructions. Residual genomic DNA was removed by 
addition of 2 μL Turbo DNA-freeTM (ThermoFisher Scientific) and 
incubation at 37  ° C for 30 min. Integrity of total RNA was assessed 
using the Agilent 2100 Bioanalyzer (Agilent Technologies). All 
samples had an RNA integrity number > 9.5.
Assessment of SETD1A RNA Knockdown
Quantitative PCR (qPCR) was used to assess the level of 
SETD1A RNA knockdown in each SETD1A siRNA condition (rel-
ative to the control siRNA condition) prior to genome-wide gene 
expression profiling. Total RNA was converted to cDNA using 
random decamers and SuperScript® III (ThermoFisher Scientific). 
SETD1A RNA expression was measured using the qPCR primers: 
F: 5′-ACCTGGCCAGATTCATCAAC-3′ and 5′-CGATC TTC-
TT CTGGGACTCG-3′. Expression of GAPDH and ACTB was si-
multaneously measured as internal control genes. The expression 
of these housekeeping genes was subsequently found not to differ 
between siRNA and control conditions in either cell line in the 
microarray data (all p > 0.05). Reactions were performed using 
SYBRTM Green PCR Master Mix (ThermoFisher Scientific) on an 
Applied Biosystems StepOnePlus Real-Time PCR system. Tripli-
cate qPCR reactions were performed to measure expression of 
each gene in each cDNA sample. Expression of each gene was mea-
sured against a standard curve constructed by serial dilution of 
pooled cDNA. Mean measures of SETD1A expression were divid-
ed by the geometric average of the mean measures for the 2 inter-
nal control genes to yield a normalized SETD1A expression value 
for each sample. Normalized SETD1A expression values were 
compared between each SETD1A siRNA condition and the nega-
tive control siRNA condition by t tests (2-tailed).
Gene Expression Profiling by Microarray
Microarray experiments were performed at Cambridge Ge-
nomic Services, University of Cambridge, using the HumanHT-12 
v4 Expression BeadChip (Illumina) according to the manufactur-
er’s instructions. Brieﬂy, 200 ng of total RNA underwent linear 
ampliﬁcation using the Illumina TotalPrep RNA Ampliﬁcation Kit 
(ThermoFisher Scientific). The concentration, purity and integrity 
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of the resulting cRNA were measured by SpectroStar and the Agi-
lent Bioanalyser. Finally cRNA was hybridized to the HumanHT-12 
v4 BeadChip overnight followed by washing, staining and scan-
ning using the Bead Array Reader (Illumina). All microarray data 
from this study have been submitted to the Gene Expression Om-
nibus (http://www.ncbi.nlm.nih.gov/geo/), with the accession No. 
GSE118941.
Identification of Differentially Expressed Probes
Data were extracted from GenomeStudio software (Illumina) 
and variance stabilizing transformation and robust spline normal-
ization applied using the lumi Bioconductor package [14]. Data 
were then log 2 transformed. Probes that were detected (detection 
p value < 0.05) in all control replicates and in all replicates of at least 
one of the knockdown conditions were retained for further analy-
sis. Probes at which gene expression in each SETD1A siRNA con-
dition differed from the siRNA control condition were identi- 
fied by individual t tests (two-tailed). Consistently with previous 
studies [6, 7] gene expression changes with p value < 0.05 in both 
SETD1A knockdown conditions and a concordant direction of ef-
fect were used for all subsequent analyses.
Validation of Gene Expression Changes
We used qPCR to confirm expression changes in selected genes 
following SETD1A knockdown using RNA extracted from the 
same samples as sent for microarray. The 10 samples that passed 
microarray QC were included for all analyses. Expression of 
EIF4A1 and FUBP3 was simultaneously measured as internal con-
trol genes (selected as control genes from the microarray results). 
Primer sequences are listed in online supplementary Table S1 (see 
www.karger.com/doi/10.1159/000/497181 for all online suppl. 
material). Reactions were carried out in triplicate, with expression 
of each gene measured against a standard curve, as described 
above. Expression changes that occurred in the same direction as 
in the microarray and with a t test p < 0.05 (1-tailed) were consid-
ered significant.
Gene Ontology/Pathway Analysis
We tested for potential enrichment of high confidence gene 
expression changes within gene ontology (GO) terms and KEGG 
pathways using the DAVID Bioinformatics Resource [15]. We 
tested for enrichment of (1) all genes shared by the two SETD1A 
siRNA conditions, (2) genes shared by the two siRNA conditions 
that were downregulated in association with SETD1A knockdown, 
and (3) genes shared by the two siRNA conditions that were up-
regulated in association with SETD1A knockdown. All gene probes 
that had a detection p value < 0.05 in all samples were used as the 
background comparison. We highlight enrichments with a false 
discovery rate (FDR) < 5%.
Grouping of categories was performed using Enrichment Map 
[16]. Nominally significant (uncorrected p < 0.05) categories iden-
tified by DAVID analysis of the downregulated genes were used as 
input for grouping by Enrichment Map using default setting. The 
cluster containing the KEGG pathway “hsa01100: metabolic path-
ways” was retained. Category size (i.e., number of genes) was used 
to scale the size of each node. The overlap coefficient was used to 
scale the size of the edges.
Overlap with brain co-expression modules [17] was performed 
using Fisher exact tests. Genes common to both studies were used 
as the background.
Gene Set Enrichment Analysis Using Schizophrenia GWAS 
Data
Differentially expressed genes shared by the two SETD1A  
siRNA conditions were used as a gene set for enrichment testing 
with MAGMA [18]. MAGMA performs tests of competitive gene 
set enrichment using summary results from GWAS, controlling 
for confounders such as gene size, gene density and linkage dis-
equilibrium. We tested for enrichment of schizophrenia common 
variant signal using summary data from a recent schizophrenia 
GWAS containing a total of 105,318 participants [19]. A window 
of 10 kb around each gene was included for single-nucleotide poly-
morphism annotations. MAGMA was run with other parameters 
set to the default. In order to control for any inflation of signal aris-
ing from use of a neural cell line, we used the set of protein-coding 
genes detected as expressed (p value < 0.05), as well as the default 
set of all protein-coding genes, for background comparisons.
Results
We used two non-overlapping siRNA (SETD1A  
siRNA #1 and siRNA #2) to knock down endogenous 
SETD1A expression in a human neuroblastoma cell line 
(SH-SY5Y). Transfection efficiency, as indexed by uptake 
of BLOCK-iTTM Alexa Fluor® Red Fluorescent Control 
oligonucleotide, was estimated to be > 90% (online suppl. 
Fig. S1). At harvest, mean SETD1A RNA expression (as 
indexed by qPCR) was reduced by 49.5% (p = 0.007) in 
the SETD1A siRNA #1 condition and 57% (p = 0.007) in 
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Fig. 1. RT-qPCR measurement of SETD1A RNA expression 96 h 
after transfection with two independent SETD1A siRNAs, com-
pared with a negative control siRNA (n = 4 per group). Relative to 
the control siRNA condition, siRNA 1 results in a 49.5% reduction 
in SETD1A expression (p = 0.007) and siRNA 2 in a reduction of 
57% (p = 0.007). Data are expressed as means and standard devia-
tions; ** p < 0.01.
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the SETD1A siRNA #2 condition, relative to the control 
siRNA condition (Fig. 1).
We detected gene expression at 16,906 microarray 
probes, corresponding to 12,514 unique Entrez gene IDs. 
Gene expression differed significantly (p < 0.05) between 
the SETD1A siRNA #1 condition and the control siRNA 
condition at 2,384 microarray probes, and between the 
SETD1A siRNA #2 and the control siRNA condition at 
4,369 microarray probes. We produced a high confidence 
set of genes affected by SETD1A knockdown by first iden-
tifying 1,184 probes that were differentially expressed in 
both siRNA conditions compared to the control condi-
tion (overlap p = 2.3 × 10–162, hypergeometric test). Next, 
we restricted this list to probes for which the direction of 
expression change was consistent between the two siRNA 
conditions. Of the 1,184 overlapping probes at p < 0.05, 
1,131 (96%) had a concordant direction of effect between 
the two siRNA conditions. Of these, 514 were upregu-
lated and 617 downregulated (online suppl. Table S2).
We sought to validate selected gene expression chang-
es using qPCR. Of the 7 selected genes, we were able to 
confirm significant directional expression changes as-
sociated with both SETD1A siRNA conditions for 5, 
and significant directional changes associated with one 
SETD1A siRNA condition for the remaining 2 (Table 1). 
These include expression changes in genes of known neu-
rodevelopmental importance such as DCX, encoding 
doublecortin, and DLX5, encoding Distal-Less Homeo-
box 5 [20, 21].
We used GO/KEGG pathway enrichment analysis to 
investigate potential overrepresentation of differentially 
expressed genes shared by the two SETD1A siRNA condi-
tions within particular biological annotations. Compared 
to the background of all detected genes, this gene set was 
significantly enriched for annotation to the KEGG path-
way “hsa01100: metabolic pathways” (FDR = 0.07%) as 
well as the GO terms “GO: 0033628∼regulation of cell ad-
hesion mediated by integrin” (FDR = 2.07%) and “GO: 
0061134∼peptidase regulator activity” (FDR = 4.49%). A 
full list of nominally significant annotations among dif-
ferentially expressed genes can be found in online supple-
mentary Table S3. We also performed separate enrich-
ment analyses for genes shared by the two SETD1A  
siRNA conditions that were either down- or upregulated 
in association with SETD1A knockdown (online suppl. 
Tables S4 and S5). Downregulated genes were also en-
riched for the KEGG pathway “hsa01100: metabolic path-
ways” (FDR = 0.23%) as well as the GO term “GO: 
0061134∼peptidase regulator activity” (FDR = 2.58%), 
but were additionally enriched for the GO terms “GO: 
0005739∼mitochondrion” (FDR = 0.29%) and “GO: 
0006506∼GPI anchor biosynthetic process” (FDR = 
3.21%). Upregulated genes were enriched for terms relat-
ing to phosphatase activity, with “GO: 0050308∼sugar-
phosphatase activity” the most significant term (FDR = 
1.36%). Along with several of the enriched GO categories, 
the KEGG pathway “hsa01100: metabolic pathways” con-
tains a large number of genes. We therefore investigated 
the relationship between all nominally significant (uncor-
rected p < 0.05) categories identified from the DAVID 
analysis of the downregulated genes using Enrichment 
Map. The KEGG pathway “hsa01100: metabolic path-
ways” shares genes with KEGG and GO categories relating 
to carbon and carbohydrate metabolism, which are then 
linked to mitochondrial terms (online suppl. Fig. S2).
Although SETD1A is part of a brain gene co-expres-
sion module enriched for gene regulators [17], we ob-
served no enrichment of dysregulated genes in these 
brain developmental modules (online suppl. Table S6). 
We also observed that its expression was apparent in 
many tissues, with little evidence for enrichment in brain 
tissue (online suppl. Fig. S3).
Table 1. Selected genes
Gene name Fold change array Fold change qPCR p value qPCR
siRNA 1 siRNA2 siRNA 1 siRNA2 siRNA 1 siRNA2
NRGN 1.41 1.3 1.21 1.04 0.00996 0.32349
DCX 1.71 1.38 1.91 1.34 0.00822 0.01213
HTR2B 0.77 0.77 0.77 0.75 0.03658 0.00316
GAP43 1.71 2.1 1.72 2.03 0.01426 0.02158
DCBLD2 0.84 0.87 0.77 0.79 0.07471 0.03908
DLX5 0.74 0.74 0.40 0.35 0.00016 0.00053
GPR64 1.8 1.98 1.87 2.47 0.00010 0.00002
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Rare LoF mutations in SETD1A appear to be a strong 
risk factor for schizophrenia, but the extent to which their 
effects converge on molecules affected by common risk 
variants for the disorder is unknown. We therefore tested 
for enrichment of schizophrenia association signal in 
genes differentially expressed following SETD1A knock-
down using summary statistics from the largest schizo-
phrenia GWAS published to date [19]. Genes that were 
differentially expressed in association with both SETD1A 
siRNA conditions were enriched for schizophrenia asso-
ciation using either the default of all protein-coding genes 
as the background comparison (p = 0.016) or all genes 
expressed in the tested SH-SY5Y cells (p = 0.036). MAG-
MA schizophrenia association statistics for differentially 
expressed genes are provided in online supplementary 
Table S7.
Discussion
LoF variants in SETD1A are the first findings from 
exome sequencing studies of schizophrenia to reach 
experiment-wide significance [3]. Although the role of 
SETD1A in regulating gene expression can be inferred 
through its function as a histone methyltransferase, the 
consequences of reduced SETD1A activity on the neural 
transcriptome have, to date, been unknown. In order to 
investigate transcriptional changes through which LoF 
mutations in SETD1A could confer risk for schizophre-
nia, we have mimicked the 50% reduction in functional 
SETD1A expression that is expected to result from such 
variants in a human neural cell line. SETD1A knockdown 
was found to bring about widespread changes in gene ex-
pression that included genes of known neurodevelop-
mental importance (e.g., DCX and DLX5). The differen-
tially expressed genes were also enriched for common 
variant association with schizophrenia. These findings 
thus suggest a degree of molecular convergence between 
this rare, strong effect schizophrenia risk factor and com-
mon susceptibility variants for the disorder.
Consistent with its predicted role as a fundamental 
regulator of gene expression, knockdown of SETD1A 
RNA by individual siRNAs resulted in thousands of 
changes in gene expression in SH-SY5Y cells. We note 
that many of these gene expression changes are likely to 
be downstream of direct regulatory effects of SETD1A at 
individual gene loci. Although widespread, high confi-
dence differentially expressed genes showed significant 
enrichment within specific pathways and cellular compo-
nents, most notably metabolic pathways and mitochon-
dria. SETD1A manipulation in other cell types resulted in 
expression changes to genes involved in DNA repair [12]. 
We found some supportive evidence for the DNA repair 
pathways in our data. “GO: 0006298∼mismatch repair” 
was nominally enriched (uncorrected p = 0.03) in the all 
and downregulated gene classes. To fully understand cell 
type specific consequences of reduced SETD1A expres-
sion, additional models will need to be used (e.g., stem 
cell-derived cell types), including those derived from dif-
ferent common variant backgrounds.
SETD1A mutations add to the growing list of histone 
lysine methyltransferases and demethylases linked to hu-
man disease [22]. The majority of LoF mutations within 
these genes have been identified in patients with intellec-
tual disability. We observed pronounced expression 
changes in several genes important for brain develop-
ment following SETD1A knockdown, including increased 
expression of DCX, which plays a crucial role in neural 
migration [20], and reduced expression of DLX5, which 
has been reported to regulate the development of cortical 
interneurons [21]. It is possible that disturbances in these 
as well as other differentially expressed neurodevelop-
mental genes contribute to the developmental learning 
difficulties as well as increased schizophrenia risk de-
scribed in SETD1A LoF mutation carriers [3].
In recent years, there have been major advances in our 
understanding of the genetic architecture of schizophre-
nia, with identification of risk alleles spanning the entire 
frequency spectrum. An important question is whether 
rare risk variants of strong effect operate through path-
ways of general relevance to schizophrenia. The data pre-
sented here suggest that effects of rare SETD1A mutations 
do indeed impinge on molecules that are more common-
ly affected in the disorder.
Web Links to Data and Software
MAGMA: https://ctg.cncr.nl/software/magma.
CLOZUK schizophrenia GWAS data: http://walters.psycm.
cf.ac.uk/.
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